Published 3 days ago • loading... • Updated 2 days ago

Amgen loses battle with Colorado over prescription drug affordability board

Summary by Dataemia

Summarize this content to 100 words In a blow to the pharmaceutical industry, a U.S. court judge ruled that a Colorado state board can proceed with plans to place limits on the prices paid for medicines, the first such decision to support the controversial attempts by some states to control their prescription drug spending. The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-se…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

Health Policy Watch

Medicine For Rare Disorder Provides Case Study Of Contradictions In Drug Development System - Health Policy Watch

The journey of the medicine, Caplacizumab – from a publicly funded scientific breakthrough to a high-cost pharmaceutical product controlled by a multinational corporation – illustrates the contradictions of the existing drug development system. It is a story of public investment, private capital, industrial consolidation, and the persistent question: Who ultimately benefits from medical innovation? At […]

2 days ago

Read Full Article